SCHEDULE 13G/A: Vanguard Group Amends Stake in CytoSorbents Corp, Reports 3.11% Passive Ownership

The Vanguard Group has filed an amended Schedule 13G, disclosing a 3.11% beneficial ownership stake in CytoSorbents Corp as of March 31, 2025.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in CytoSorbents Corp.
• As of March 31, 2025, The Vanguard Group beneficially owns 1,949,551 shares of CytoSorbents Corp's Common Stock.
• This represents 3.11% of the class of securities.
• Vanguard holds sole dispositive power over 1,935,686 shares and shared dispositive power over 13,865 shares.
• Vanguard holds no sole or shared voting power over these shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates continued passive investment by a major institutional investor, which is generally a positive sign of stability and liquidity for the stock, though it provides no new operational or financial news about the company itself.

Positives

• A major institutional investor, The Vanguard Group, maintains a significant stake in CytoSorbents Corp, indicating continued confidence in the company's long-term prospects.
• The filing confirms that Vanguard's ownership is for investment purposes in the ordinary course of business, not for control, which suggests stability in the ownership structure and no immediate activist intent.

Negatives

• The filing itself does not contain negative financial or operational information about CytoSorbents Corp; it only reports beneficial ownership.

Risks

• The document is a beneficial ownership report and does not explicitly state risks related to CytoSorbents Corp's operations or financial health.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding CytoSorbents Corp's future performance or outlook.

Management Comments

• The filing includes a certification by Ashley Grim, Head of Global Fund Administration for The Vanguard Group, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This filing reflects a routine disclosure by a large institutional asset manager, The Vanguard Group, regarding its passive investment in CytoSorbents Corp. It indicates that CytoSorbents Corp remains part of Vanguard's investment portfolios, likely through various index or actively managed funds, aligning with broader trends of institutional investment in the biotechnology or medical device sector.

Comparison to Industry Standards

• This document is a standard beneficial ownership filing (Schedule 13G/A) by a passive institutional investor.
• It does not provide company-specific performance metrics that can be directly compared to industry peers or global benchmarks.
• The 3.11% stake is a typical passive investment size for a large fund manager like Vanguard in a company of CytoSorbents Corp's scale, consistent with their investment strategies across various sectors.

Stakeholder Impact

• Shareholders: The continued passive investment by a major institutional holder like Vanguard can provide a degree of stability and liquidity for the stock.
• Company Management: Awareness of significant institutional ownership can influence corporate governance considerations, though Vanguard explicitly states its investment is not for control.

Next Steps

• The document does not specify future actions or milestones for CytoSorbents Corp. The Vanguard Group will continue to file amendments if its beneficial ownership significantly changes.

Key Dates

Keywords

CytoSorbents Corp, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing